The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

by | Jan 29, 2013 | Journal Club

Journal Club Summary Methodology: 2.5/5 Usefulness: 2.5/5 IST-3 collaborative group, Sandercock P, Wardlaw JM, et al. Lancet. 2012 Jun 23;379(9834):2352-63. Article Link   This international, multicenter, randomized, open-treatment trial was aimed at detecting...